Trevi Therapeutics, Inc.
TRVI
$14.76
-$0.12-0.81%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 23.44% | 5.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 45.91% | -26.56% | |||
| Operating Income | -45.91% | 26.56% | |||
| Income Before Tax | -58.57% | 29.49% | |||
| Income Tax Expenses | -25.00% | -6.67% | |||
| Earnings from Continuing Operations | -58.63% | 29.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -58.63% | 29.54% | |||
| EBIT | -45.91% | 26.56% | |||
| EBITDA | -46.02% | 26.58% | |||
| EPS Basic | -58.39% | 29.64% | |||
| Normalized Basic EPS | -58.38% | 29.67% | |||
| EPS Diluted | -58.39% | 29.64% | |||
| Normalized Diluted EPS | -58.38% | 29.67% | |||
| Average Basic Shares Outstanding | 0.06% | 0.27% | |||
| Average Diluted Shares Outstanding | 0.06% | 0.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||